Immunovant Posts Narrower-Than-Expected Q2 Loss of $97.2M
IMVT sits 31% above its 52-week low of $21.43 on elevated volume (1.9× avg).
Summary
Immunovant reported a Q2 net loss of $97.246 million, well narrower than the IBES estimate of a $152.9 million loss. Operating expenses came in at $104.155 million and basic EPS was -$0.47. The narrower loss is a modest positive, but the real story for this name remains the IMVT-1402 program after the September CLE proof-of-concept study missed its primary endpoint. Cash burn is the number that matters here: the prior quarter posted a $153.2 million net loss on surging R&D, so a lighter Q2 loss suggests spending is coming in below the prior run rate.
At the time of this announcement, IMVT was trading at $28.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3B. The 52-week trading range was $21.43 to $45.42. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.